BiotechTube

Cinacalcet HCl

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyperparathyroidism; Secondary, Renal

Conditions

Hyperparathyroidism; Secondary, Renal

Trial Timeline

Apr 19, 2017 → Sep 6, 2019

NCT ID
NCT03123406

About Cinacalcet HCl

Cinacalcet HCl is a approved stage product being developed by Kyowa Kirin for Hyperparathyroidism; Secondary, Renal. The current trial status is completed. This product is registered under clinical trial identifier NCT03123406. Target conditions include Hyperparathyroidism; Secondary, Renal.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT03123406ApprovedCompleted
NCT01460030Phase 3Completed

Competing Products

20 competing products in Hyperparathyroidism; Secondary, Renal

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
52
KHK7580 + KRN1493Kyowa KirinPhase 2/3
65
KHK7580Kyowa KirinPhase 1
33
KHK7580Kyowa KirinPhase 1/2
41
KHK7580Kyowa KirinPhase 3
77
KHK7580Kyowa KirinPhase 3
77
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
77
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
52
Paricalcitol + CalcitriolAbbViePre-clinical
23
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
77
Paricalcitol + CalcifediolAbbVieApproved
85
Paricalcitol + Darbepoetin alfaAbbVieApproved
85
Alendronate 70mg weeklyMerckApproved
85
EtelcalcetideAmgenPhase 3
76
Cinacalcet + PlaceboAmgenPhase 2
51
Cinacalcet + PlaceboAmgenPhase 3
76
Etelcalcetide + PlaceboAmgenPhase 1
32
Sensipar (Cinacalcet HCl)AmgenPhase 2
51
AMG 073 + PlaceboAmgenPhase 3
76
cinacalcetAmgenPhase 3
76

Other Products from Kyowa Kirin

KRN23Approved
85
Istradefylline PillApproved
85
MogamulizumabApproved
85
KRN23Approved
85
KHK4827-Active + KHK4827-PlaceboApproved
85